Key facts
- CamGene’s last known valuation is $8.8M (Oct 2025).
- It has raised $4.9M; the latest was Early Stage VC ($4.8M) in Mar 2026.
- Notable investors include Future Planet Capital, Parkwalk Advisors, Cambridge Angels, Cambridge Enterprise Ventures, UK Innovation & Science Seed Fund — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for CamGene
- ·The full record, as it builds
Funding rounds
No funding rounds for CamGene are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CamGene
Developer of nanoparticle-based mRNA therapeutic drugs designed for patients who have lost their hearing. The company's lipid nanoparticle-based mRNA technology precisely targets ear cells to deliver therapeutic proteins for the regeneration and protection of key cells in the cochlea, all at a cost that will make it feasible to create an accessible mass-market medicine, enabling doctors to treat the underlying cellular dysfunction, which is the root cause of hearing loss.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2023
- Employees
- 8
- Website
- camgenetx.com/
- Ownership
- Privately Held (backing)
CamGene doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CamGene shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CamGene in its N-PORT filings yet. We sweep new filings monthly.